Endocrinology

Standard of Care and Treatment Strategies

At a Glance

FPLD4 treatment cannot correct the underlying genetic change, so care focuses on a tailored low-fat, high-fiber diet, control of blood sugar and triglycerides, selected medicines such as metreleptin, and regular liver, kidney, and heart monitoring.

Because the genetic mutation in FPLD4 cannot be “fixed,” treatment focuses on managing the metabolic consequences caused by the body’s inability to store fat correctly. Your care team—ideally led by an endocrinologist with experience in rare diseases—will aim to protect your liver, pancreas, and heart by controlling your blood sugar and fats ^[1]^[2].

The Foundation: Dietary Management

Diet is the most critical tool in managing FPLD4, particularly for controlling triglycerides (fats in the blood).

Fat Restriction: A balanced, low-fat diet is standard. For those with severe hypertriglyceridemia, doctors may recommend a very strict limit on fat intake, which is individualized under the supervision of a registered dietitian, to prevent inflammation of the pancreas (pancreatitis) ^[3]^[4].
Carbohydrate Quality: Because of high insulin resistance, choosing complex carbohydrates with high fiber is preferred over simple sugars, which can further spike triglyceride levels ^[2].
Alcohol Avoidance: Alcohol can significantly worsen triglyceride levels and should be strictly limited or avoided entirely ^[5].

First-Line Medications

Pharmacotherapy for FPLD4 typically begins with well-established medications for diabetes and heart health.

Metformin and Insulin: Metformin may be useful for insulin resistance ^[6]. However, substantial insulin resistance or severe hyperglycemia may require insulin, sometimes at high doses, as well as individualized diabetes therapy; do not delay or stop insulin when it is medically indicated ^[1].
Statins and Fibrates: Statins are used primarily to reduce cardiovascular risk ^[7]. Fibrates (like fenofibrate) are used specifically to lower triglyceride levels by helping the body clear fats from the blood ^[8]. Combining a statin with certain fibrates requires monitoring for muscle toxicity.

Newer Metabolic Adjuncts

Recent consensus guidelines have introduced newer classes of drugs that may offer additional benefits for patients with partial lipodystrophy.

GLP-1 Receptor Agonists: These medications (often used for type 2 diabetes) have limited observational evidence in lipodystrophy showing promise in lowering HbA1c, triglycerides, and liver enzymes ^[9]. However, they can cause nausea or gastrointestinal distress ^[9].
SGLT2 Inhibitors: In some studies of partial lipodystrophy, they have been associated with lower blood pressure and improved liver markers ^[10]^[11]. However, they can cause euglycemic diabetic ketoacidosis, particularly during illness, fasting, or strict carbohydrate restriction. Follow specific sick-day withholding guidance carefully.

Specialized and Emerging Therapies

For patients with severe disease that does not respond to standard care, specialized treatments may be considered.

Metreleptin (Leptin Replacement)

Metreleptin is a synthetic version of the hormone leptin, which is normally produced by fat cells. Because you have less fat in certain areas, your leptin levels may be very low.

Eligibility: It is NOT a universal treatment for FPLD4. Regulatory approval differs by country, and its use in partial lipodystrophy may be off-label or limited to selected patients who also have severe metabolic complications (like uncontrolled diabetes or high triglycerides) ^[12]^[13]. There is no universally accepted leptin cutoff for FPLD4.
Dosage: If prescribed, it is a daily injection. Dosing must follow the current local prescribing information and a lipodystrophy specialist ^[14]^[15].
Side Effects: Safety issues that require specialist monitoring include low blood sugar (hypoglycemia), hypersensitivity, anti-metreleptin or neutralizing antibodies, and product-specific warnings regarding malignancy ^[13]^[16].

Volanesorsen

For those with extremely high triglycerides at risk for pancreatitis, volanesorsen (an apoC-III inhibitor) has shown triglyceride reductions in research, but it is primarily an indication- and jurisdiction-specific therapy for familial chylomicronemia syndrome ^[17]. Its use in FPLD4 is not routine and may be off-label or confined to specialist assessment or clinical trials, and it requires strict platelet and laboratory monitoring ^[18].

Treatment for FPLD4 is a marathon, not a sprint. Regular annual screenings for kidney, liver, and heart health are essential to ensure your regimen remains effective as the condition evolves ^[1].

Common questions in this guide

What is the standard treatment for PLIN1-related familial partial lipodystrophy?

There is no treatment that repairs the underlying PLIN1-related genetic change. Care focuses on a tailored diet and medicines that control blood sugar and triglycerides while reducing risks to the liver, pancreas, and heart. Regular kidney, liver, and heart checks help clinicians adjust the plan over time.

What diet is recommended for FPLD4?

A balanced low-fat diet is the foundation of treatment. When triglycerides are very high, a clinician may recommend a stricter individualized fat limit with help from a registered dietitian to lower pancreatitis risk. High-fiber complex carbohydrates are preferred over simple sugars, and alcohol should be strictly limited or avoided.

Which medicines are used to manage FPLD4?

Metformin may help with insulin resistance, while insulin may be needed for severe insulin resistance or high blood sugar. Statins are used mainly to lower heart risk, and fibrates such as fenofibrate help lower triglycerides. GLP-1 receptor agonists and SGLT2 inhibitors may be considered in selected patients, but they require individualized safety guidance.

Who might be eligible for metreleptin treatment in FPLD4?

Metreleptin is not a universal treatment for FPLD4. A specialist may consider it for selected patients with partial lipodystrophy and severe metabolic complications, such as uncontrolled diabetes or very high triglycerides; approval and off-label use differ by country. There is no universally accepted leptin level that determines eligibility.

Is volanesorsen routinely used for FPLD4-related high triglycerides?

No. Volanesorsen is primarily an indication-specific treatment for familial chylomicronemia syndrome, so its use in FPLD4 is not routine and may be off-label, limited to specialist assessment, or part of a clinical trial. It also requires platelet and laboratory monitoring.

What medication safety issues should people with FPLD4 know about?

SGLT2 inhibitors can cause diabetic ketoacidosis even when blood sugar is not very high, especially during illness, fasting, or strict carbohydrate restriction, so follow the prescribed sick-day instructions. Metreleptin can cause low blood sugar, allergic reactions, and treatment-related antibodies, while some statin-fibrate combinations can increase muscle toxicity. Ask your care team what symptoms and tests require prompt attention.

Get notified when new evidence is published on PLIN1-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.
PMID: 27710244
2
Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.
Lambadiari V, Bargiota A, Kanaka-Gantenbein C, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(6)):1008-1016 doi:10.1016/j.eprac.2026.02.014.
PMID: 41713690
3
Genotype - phenotype correlation in an adolescent girl with pathogenic PPARy genetic variation that caused severe hypertriglyceridemia and early onset type 2 diabetes.
Gutierrez Alvarez A, Yachelevich N, Kohn B, Brar PC
Annals of pediatric endocrinology & metabolism 2021; (26(4)):284-289 doi:10.6065/apem.2142056.028.
PMID: 34991302
4
Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O, Wierzbicki AS
Drug design, development and therapy 2020; (14()):2623-2636 doi:10.2147/DDDT.S224771.
PMID: 32753844
5
A Comprehensive Update on the Chylomicronemia Syndrome.
Goldberg RB, Chait A
Frontiers in endocrinology 2020; (11()):593931 doi:10.3389/fendo.2020.593931.
PMID: 33193106
6
Lipodystrophic syndromes: From diagnosis to treatment.
Sollier C, Vatier C, Capel E, et al.
Annales d'endocrinologie 2020; (81(1)):51-60 doi:10.1016/j.ando.2019.10.003.
PMID: 31982105
7
Hypertriglyceridemia.
Chait A
Endocrinology and metabolism clinics of North America 2022; (51(3)):539-555 doi:10.1016/j.ecl.2022.02.010.
PMID: 35963627
8
Advances in the care of lipodystrophies.
Shamsudeen I, Hegele RA
Current opinion in endocrinology, diabetes, and obesity 2022; (29(2)):152-160 doi:10.1097/MED.0000000000000695.
PMID: 34839327
9
Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.
Lamothe S, Belalem I, Vantyghem MC, et al.
Diabetes, obesity & metabolism 2025; (27(4)):1815-1825 doi:10.1111/dom.16175.
PMID: 39829337
10
Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy.
Bansal R, Cochran E, Startzell M, Brown RJ
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(6)):610-614 doi:10.1016/j.eprac.2022.03.006.
PMID: 35301125
11
Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network.
Robert L, Belalem I, Vigouroux C, et al.
Diabetes, obesity & metabolism 2026; (28(11)):10318-10329 doi:10.1111/dom.71126.
PMID: 42618535
12
Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T, Cochran E, Gorden P, Brown RJ
The Journal of clinical endocrinology and metabolism 2015; (100(5)):1802-10 doi:10.1210/jc.2014-4491.
PMID: 25734254
13
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
Oral EA, Gorden P, Cochran E, et al.
Endocrine 2019; (64(3)):500-511 doi:10.1007/s12020-019-01862-8.
PMID: 30805888
14
Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
Ajluni N, Dar M, Xu J, et al.
Journal of diabetes & metabolism 2016; (7(3)).
PMID: 27642538
15
Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ, Meehan CA, Cochran E, et al.
The Journal of clinical endocrinology and metabolism 2017; (102(5)):1511-1519 doi:10.1210/jc.2016-3628.
PMID: 28324110
16
New advances in the treatment of generalized lipodystrophy: role of metreleptin.
Rodriguez AJ, Mastronardi CA, Paz-Filho GJ
Therapeutics and clinical risk management 2015; (11()):1391-400 doi:10.2147/TCRM.S66521.
PMID: 26396524
17
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
Oral EA, Garg A, Tami J, et al.
Journal of clinical lipidology 2022; (16(6)):833-849 doi:10.1016/j.jacl.2022.08.008.
PMID: 36402670
18
Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.
Lightbourne M, Startzell M, Bruce KD, et al.
Journal of clinical lipidology 2022; (16(6)):850-862 doi:10.1016/j.jacl.2022.06.011.
PMID: 36195542

This page is for informational purposes only and does not constitute medical advice. An endocrinologist and registered dietitian should tailor diet, medicines, and monitoring to your triglycerides, blood sugar, and other health risks.